Education. Empowerment. Natural Relief.
About Us |  Contact Us |  FAQs
We're here to help. Call: 1-800-731-6327
 
PMDD Birth Control

Birth Control for PMDD: Yasmin®, Yaz®& Their Side Effects—References

  • Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev. 2012;2:CD006586.
  • Marr J, Niknian M, Shulman LP, Lynen R. Premenstrual dysphoric disorder symptom cluster improvement by cycle with the combined oral contraceptive ethinylestradiol 20 mcg plus drospirenone 3 mg administered in a 24/4 regimen. Contraception. 2011;84:81-86.
  • Marr J, Heinemann K, Kunz M, Rapkin A. Ethinyl estradiol 20μg/drospirenone 3mg 24/4 oral contraceptive for the treatment of functional impairment in women with premenstrual dysphoric disorder. Int J Gynaecol Obstet. 2011;113:103-107.
  • Rendas-Baum R, Yang M, Gricar J, Wallenstein GV. Cost-effectiveness analysis of treatments for premenstrual dysphoric disorder. Appl Health Econ Health Policy. 2010;8:129-140.
  • Breech LL, Braverman PK. Safety, efficacy, actions, and patient acceptability of drospirenone/ethinyl estradiol contraceptive pills in the treatment of premenstrual dysphoric disorder. Int J Womens Health. 2010;1:85-95.
  • Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev. 2009:CD006586.
  • Rapkin AJ. YAZ in the treatment of premenstrual dysphoric disorder. J Reprod Med. 2008;53:729-741.
  • Joffe H, Petrillo LF, Viguera AC, et al. Treatment of premenstrual worsening of depression with adjunctive oral contraceptive pills: a preliminary report. J Clin Psychiatry. 2007;68:1954-1962.
  • De Berardis D, Serroni N, Salerno RM, Ferro FM. Treatment of premenstrual dysphoric disorder (PMDD) with a novel formulation of drospirenone and ethinyl estradiol. Ther Clin Risk Manag. 2007;3:585-590.
  • Rapkin AJ, McDonald M, Winer SA. Ethinyl estradiol/drospirenone for the treatment of the emotional and physical symptoms of premenstrual dysphoric disorder. Womens Health (Lond Engl). 2007;3:395-408.
  • Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception. 2005;72:414-421.
  • Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol. 2005;106:492-501.
  • Dinger JC, Heinemann LA, Kühl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception. 2007;75:344-354.
  • Parkin L, Sharples K, Hernandez RK, Jick SS. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ. 2011;342:d2139.
  • Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ. 2011;342:d2151.
  • Risoleti, E.V.I., Giuffrida, L., Iozza, I., Garofalo, G., Valenti, O., Napoli, C. Efficacy Vitex agnus-castus in the premenstrual syndrome: Our experience. [Efficacia di Vitex agnus-castus nella sindrome premestruale: La nostra esperienza.] Giornale Italiano di Ostetricia e Ginecologia. 2011;33(4):227-231
  • Walker AF, De Souza MC, Vickers MF, Abeyasekera S, Collins ML, Trinca LA. Magnesium supplementation alleviates premenstrual symptoms of fluid retention. J Womens Health. 1998;7:1157-1165.
  • Kashanian M, Mazinani R, Jalalmanesh S. Pyridoxine (vitamin B6) therapy for premenstrual syndrome. Int J Gynaecol Obstet. 2007;96:43-44.
  • Ghanbari Z, Haghollahi F, Shariat M, Foroshani AR, Ashrafi M. Effects of calcium supplement therapy in women with premenstrual syndrome. Taiwan J Obstet Gynecol. 2009;48:124-129.

Last Modified: April 3, 2014

Back to: Birth Control for PMDD: Yasmin®, Yaz®& Their Side Effects

DISCLAIMER

The information and contents contained in this Web site has not been evaluated by the FDA. Products are not intended to diagnose, treat, cure, or prevent any disease. If you are pregnant, intend to become pregnant, or nursing, please consult a physician before taking any dietary supplement. If taking prescription drugs, consult your healthcare practitioner prior to use. You must be 18 years or older to purchase products. Individual results do vary.

PMS & PMDD Stories

"Now I'm a happy camper."

Jennifer used to not want to get out of bed, PMS made her so depressed. Now she's forgotten what PMS feels like. [more]

PMS Comfort Blog

Discrimination Increases PMDD, Severe PMS, In Minority Women

September 6, 2011

When minority women feel discrimination on the basis of gender, race, weight, or other factors, they’re more likely to have PMDD. [more]

 
Contact Us
We're here to help

1-800-731-6327